First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
Titel:
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
Auteur:
Özgüroğlu, Mustafa Kilickap, Saadettin Sezer, Ahmet Gümüş, Mahmut Bondarenko, Igor Gogishvili, Miranda Nechaeva, Marina Schenker, Michael Cicin, Irfan Ho, Gwo Fuang Kulyaba, Yaroslav Zyuhal, Kasimova Scheusan, Roxana-Ioana Garassino, Marina Chiara He, Xuanyao Kaul, Manika Okoye, Emmanuel Li, Yuntong Li, Siyu Pouliot, Jean-Francois Seebach, Frank Lowy, Israel Gullo, Giuseppe Rietschel, Petra